Subscribe to RSS
DOI: 10.1055/s-0043-1766093
2023 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles
Welcome to the latest of our Eberhard F. Mammen award announcements. As noted in previous editorials ([Table 1]), Thieme, the publisher of Seminars in Thrombosis and Hemostasis (STH), has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard Mammen ([Fig. 1]), and in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades. These awards began in 2009, under two categories, “Most Popular Article Awards” and “Young Investigator Awards.” Accordingly, 2023 represents 15 years of award presentations ([Table 1]). Current details and conditions of the award can be summarized as:
➢ Most popular article awards: Awarded to the authors of the most popular articles published in STH in the preceding 2 years as captured in the preceding year. The awards are determined by the editor in chief on the basis of user statistics from Thieme e-Journals. Prefaces, Errata, Letters to the Editor, Editorials, Commentaries, and previous award-winning articles are excluded from further consideration of these awards, which currently comprise two categories—one for “Free Access” articles and another for a “General Category.” There are two major cash prizes of US$ 1,000 for each category. In addition, winners of the “General Category” awards are granted “Free Access” status for these articles thereafter.
➢ Young investigator awards: Best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen (up to six cash prizes of US$ 1,000 in any year). There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other article related to the topic of their presentation (or as otherwise agreed) for publication in STH. Previous award winners are excluded from a second award to enable more individuals to be recognized. After nominations are received, the awardees are selected by a vote of the senior editors of STH. Any potential conflicts of interest are managed by first identifying these, and then excluding those with potential conflicts from voting. Finally, given the current coronavirus disease 2019 (COVID-19) pandemic, many international congresses have become virtual meetings, and accordingly, virtual meeting presentations can also be considered for the award.
Further details of the awards and the award winners are posted online (https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077), and previous award winner announcements are also available in print (see [Table 1]).
It is therefore with great pleasure that we would like to announce the latest winners of the 2023 Eberhard F. Mammen awards for the most popular articles from STH, as downloaded in 2022 and as published in the period of 2021–2022 inclusive.
2023 “Most Popular” Article Awards
As mentioned, the Most Popular awards are given to the authors of the most popular articles published in STH as determined on the basis of user statistics from the publisher of this journal and covering the preceding 2-year publication period, as captured in the preceding year. Thus, the 2023 “Most Popular” awards are granted to the most popular articles, as downloaded in 2022, and as published in the years 2021–2022 inclusive. Previous Eberhard F. Mammen award winning articles are listed in [Table 2]. These articles are currently freely available online (https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077), and no longer qualify for future awards, although some will continue to appear in the most popular download statistics provided by the publisher.
Year |
Awarded for |
|---|---|
2009 |
Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005;31(4):381–392 |
2009 |
Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost 2006;32(8):803–809 |
2010 |
Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 2008;34(1):39–57 |
2010 |
Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 2008;34(1):86–96 |
2010 |
Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008;34(1):58–73 |
2011 |
Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost 2009;35(5):515–524 |
2011 |
Mariani G, Bernardi F. Factor VII deficiency. Semin Thromb Hemost 2009;35(4):400–406 |
2012 |
Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the “French paradox.” Semin Thromb Hemost 2010;36(1):59–70 |
2012 |
Rak J. Microparticles in cancer. Semin Thromb Hemost 2010;36(8):888–906 |
2013 |
Fava C, Montagnana M, Favaloro EJ, Guidi GC, Lippi G. Obstructive sleep apnea syndrome and cardiovascular diseases. Semin Thromb Hemost 2011;37(3):280–297 |
2013 |
Tufano A, Guida A, Dario Di Minno MN, Prisco D, Cerbone AM, Minno GD. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: a review of the literature. Semin Thromb Hemost 2011;37(3):267–274 |
2014 |
Salmela B, Joutsi-Korhonen L, Armstrong E, Lassila R. Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost 2012;38(1):23–30 |
2014 |
Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. Semin Thromb Hemost 2012;38(1):47–54 |
2014 |
Kenet G, Aronis S, Berkun Y, Bonduel M, Chan A, Goldenberg NA, Holzhauer S, Iorio A, Journeycake J, Junker R, Male C, Manco-Johnson M, Massicotte P, Mesters R, Monagle P, van Ommen H, Rafini L, Simioni P, Young G, Nowak-Göttl U. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. Semin Thromb Hemost 2011;37(7):802–809 |
2015 |
Tapson VF. Thrombolytic therapy for acute pulmonary embolism. Semin Thromb Hemost 2013;39(4):452–458 |
2015 |
George JN, Charania RS. Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia. Semin Thromb Hemost 2013;39(2):153–160 |
2015a |
Hylek EM. Anticoagulation therapy for atrial fibrillation. Semin Thromb Hemost 2013;39(2):147–152 |
2015a |
Rojas-Hernandez CM, Garcia DA. The novel oral anticoagulants. Semin Thromb Hemost 2013;39(2):117–126 |
2016 |
de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013;39(6):585–595 |
2016 |
Sethi S, Fervenza FC. Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost 2014;40(4):416–421 |
2016a |
Bates SM. D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. Semin Thromb Hemost 2012;38(7):673–682 |
2016a |
Lippi G, Favaloro EJ, Meschi T, Mattiuzzi C, Borghi L, Cervellin G. E-cigarettes and cardiovascular risk: beyond science and mysticism. Semin Thromb Hemost 2014;40(1):60–65 |
2017 |
Boonyawat K, Crowther MA. Venous thromboembolism prophylaxis in critically ill patients. Semin Thromb Hemost 2015;41(1):68–74 |
2017 |
Levi M, Poll TV. Coagulation in patients with severe sepsis. Semin Thromb Hemost 2015;41(1):9–15 |
2017a |
Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 2014;40(2):163–171 |
2017a |
Warkentin TE. Heparin-Induced Thrombocytopenia in Critically Ill Patients. Semin Thromb Hemost. 2015;41(1):49–60 |
2017b |
Favaloro EJ, Lippi G. Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors. Semin Thromb Hemost 2015;41(2):208–227 |
2018 |
Gremmel T, Frelinger AL III, Michelson AD. Platelet physiology. Semin Thromb Hemost 2016;42(3):191–204 |
2018 |
Mallett SV. Clinical utility of viscoelastic tests of coagulation (TEG/ROTEM) in patients with liver disease and during liver transplantation. Semin Thromb Hemost 2015;41(5):527–537 |
2018[a] |
Cuker A, Prak ET, Cines DB. Can immune thrombocytopenia be cured with medical therapy? Semin Thromb Hemost 2015;41(4):395–404 |
2018[a] |
Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. Semin Thromb Hemost 2014;40(1):106–114 |
2019 |
Klil-Drori AJ, Tagalakis V. Direct oral anticoagulants in end-stage renal disease. Semin Thromb Hemost 2018;44(4):353–363 |
2019 |
Kitchen S, Tiefenbacher S, Gosselin R. Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies. Semin Thromb Hemost 2017;43(3):331–337 |
2019[a] |
Kell DB, Pretorius E. To what extent are the terminal stages of sepsis, septic shock, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome actually driven by a prion/amyloid form of fibrin? Semin Thromb Hemost 2018;44(3):224–238 |
2019[a] |
Chighizola CB, Raimondo MG, Meroni PL. Management of thrombotic antiphospholipid syndrome. Semin Thromb Hemost 2018;44(5):419–426 |
2020 |
Kumar KR, Cowley MJ, Davis RL. Next-generation sequencing and emerging technologies. Semin Thromb Hemost 2019;45(7):661–673 |
2020 |
Russo V, Attena E, Mazzone C, Esposito F, Parisi V, Bancone C, Rago A, Nigro G, Sangiuolo R, D'Onofrio A. Nonvitamin K antagonist oral anticoagulants use in patients with atrial fibrillation and bioprosthetic heart valves/prior surgical valve repair: a multicenter clinical practice experience. Semin Thromb Hemost 2018;44(4):364–369 |
2020[a] |
Lippi G, Favaloro EJ, Sanchis-Gomar F. Sudden cardiac and noncardiac death in sports: epidemiology, causes, pathogenesis, and prevention. Semin Thromb Hemost 2018;44(8):780–786 |
2020[a] |
Schreiber K, Breen K, Cohen H, Jacobsen S, Middeldorp S, Pavord S, Regan L, Roccatello D, Robinson SE, Sciascia S, Seed PT, Watkins L, Hunt BJ. HYdroxychloroquine to improve pregnancy outcome in women with AnTIphospholipid Antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies. Semin Thromb Hemost 2017;43(6):562–571 |
2021 |
Iba T, Levi M, Levy JH. Sepsis-induced coagulopathy and disseminated intravascular coagulation. Semin Thromb Hemost 2020;46(1):89–95 |
2021 |
Thomas J, Kostousov V, Teruya J. Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation. Semin Thromb Hemost 2018;44(1):20–29 |
2021[a] |
Gosselin RC, Adcock D, Dorgalaleh A, Favaloro EJ, Lippi G, Pego JM, Regan I, Siguret V. International Council for Standardization in Haematology Recommendations for hemostasis critical values, tests, and reporting. Semin Thromb Hemost 2020;46(4):398–409 |
2021[a] |
Gosselin RC, Marlar RA. Preanalytical variables in coagulation testing: setting the stage for accurate results. Semin Thromb Hemost 2019;45(5):433–448 |
2022 |
Abildgaard A, Madsen SA, Hvas AM. Dosage of anticoagulants in obesity: recommendations based on a systematic review. Semin Thromb Hemost 2020;46(8):932–969 |
2022 |
Grottke O, Mallaiah S, Karkouti K, Saner F, Haas T. Fibrinogen supplementation and its indications. Semin Thromb Hemost 2020;46(1):38–49 |
2022[a] |
Di Minno A, Ambrosino P, Calcaterra I, Di Minno MND. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin Thromb Hemost 2020;46(7):763–771 |
2022[a] |
Allaoui A, Khawaja AA, Badad O, Naciri M, Lordkipanidzé M, Guessous F, Zaid Y. Platelet function in viral immunity and SARS-CoV-2 infection. Semin Thromb Hemost 2021;47(4):419–426 |
a New “Free Access” category created in 2015.
b This paper qualified as the “Most Popular” award based on download data provided by the publisher; however, as this paper was written by the journal editor in chief, there was an obvious conflict of interest, and the award was officially declined. This paper is listed here merely as a statement of record.
There is also an increasingly recognized trend to publish articles under an open-access model, and these, as well as other freely available articles, will therefore have an “inequitable advantage” over other “non-open access/non-freely available” articles in terms of potential for downloads or perceived popularity due to their free accessibility. Accordingly, the publisher of STH has established separate categories of the Most Popular Award for “Free Access” articles and an alternate “General Category” (non-free access). Consequently, the most popular articles from each category are identified separately. [Tables 3] and [4], respectively, list the top 15 downloaded articles from STH in 2022 (from 2021 and 2022 inclusive), as eligible for either the “free access” ([Table 3])[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] or the “General Category” ([Table 4])[16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] awards. As expected, the majority of the “Free Access” articles were related to COVID-19. The top downloaded article, by Allaoui et al, on platelet function in viral immunity and SARS-CoV-2 infection won a 2022 Most Popular award, and is thus ineligible for the 2023 award. The next top downloaded article by Lippi and Favaloro, on cerebral venous thrombosis developing after COVID-19 vaccination, is eligible for the 2023 Most Popular award; however, given I was an author of the article, and I am also the Editor in Chief of the journal, with this representing an obvious conflict, I will decline the associated cash prize, as will also Professor Lippi. The Publisher has agreed to present this cash prize instead to a “third” article for this category. Therefore, the 2023 Eberhard F. Mammen award winners for most popular article (2021/2022 inclusive, as downloaded in 2022) are as follows:
1 |
Allaoui A, Khawaja AA, Badad O, Naciri M, Lordkipanidzé M, Guessous F, Zaid Y. Platelet function in viral immunity and SARS-CoV-2 infection. Semin Thromb Hemost 2021;47(4):419–426 |
2 |
Lippi G, Favaloro EJ. Cerebral venous thrombosis developing after COVID-19 vaccination: VITT, VATT, TTS, and more. Semin Thromb Hemost 2022;48(1):8–14 |
3 |
Engelen MM, Vandenbriele C, Balthazar T, Claeys E, Gunst J, Guler I, Jacquemin M, Janssens S, Lorent N, Liesenborghs L, Peerlinck K, Pieters G, Rex S, Sinonquel P, Van der Linden L, Van Laer C, Vos R, Wauters J, Wilmer A, Verhamme P, Vanassche T. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost 2021;47(4):362–371 |
4 |
Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: a systematic review and an updated meta-analysis. Semin Thromb Hemost 2021;47(4):372–391 |
5 |
Favaloro EJ, Henry BM, Lippi G. Is lupus anticoagulant a significant feature of COVID-19? A critical appraisal of the literature. Semin Thromb Hemost 2022;48(1):55–71 |
6 |
Abate V, Casoria A, Rendina D, Muscariello R, Nuzzo V, Vargas M, Servillo G, Venetucci P, Conca P, Tufano A, Galletti F, Di Minno G. Spontaneous muscle hematoma in patients with COVID-19: a systematic literature review with description of an additional case series. Semin Thromb Hemost 2022;48(1):100–108 |
7 |
Bahraini M, Dorgalaleh A. The impact of SARS-CoV-2 infection on blood coagulation and fibrinolytic pathways: a review of prothrombotic changes caused by COVID-19. Semin Thromb Hemost 2022;48(1):19–30 |
8 |
Favaloro EJ, Henry BM, Lippi G. Increased VWF and decreased ADAMTS-13 in COVID-19: creating a milieu for (micro)thrombosis. Semin Thromb Hemost 2021;47(4):400–418 |
9 |
Fernández-Capitán C, Barba R, Díaz-Pedroche MDC, Sigüenza P, Demelo-Rodriguez P, Siniscalchi C, Pedrajas JM, Farfán-Sedano AI, Olivera PE, Gómez-Cuervo C, Llamas P, Villares P, Sanchez O, López-Reyes R, Catella J, Bikdeli B, Weinberg I, Tafur AJ, Jiménez D, Monreal M. Presenting characteristics, treatment patterns, and outcomes among patients with venous thromboembolism during hospitalization for COVID-19. Semin Thromb Hemost 2021;47(4):351–361 |
10 |
Favaloro EJ, Henry BM, Lippi G. COVID-19 and antiphospholipid antibodies: time for a reality check? Semin Thromb Hemost 2022;48(1):72–92 |
11 |
Grobbelaar LM, Kruger A, Venter C, Burger EM, Laubscher GJ, Maponga TG, Kotze MJ, Kwaan HC, Miller JB, Fulkerson D, Huff W, Chang E, Wiarda G, Bunch CM, Walsh MM, Raza S, Zamlut M, Moore HB, Moore EE, Neal MD, Kell DB, Pretorius E. Relative hypercoagulopathy of the SARS-CoV-2 beta and delta variants when compared with the less severe omicron variants is related to TEG parameters, the extent of fibrin amyloid microclots, and the severity of clinical illness. Semin Thromb Hemost 2022;48(7):858–868 |
12 |
Onorato D, Pucci M, Carpene G, Henry BM, Sanchis-Gomar F, Lippi G. Protective effects of statins administration in European and North American patients infected with COVID-19: a meta-analysis. Semin Thromb Hemost 2021;47(4):392–399 |
13 |
Hvas CL, Larsen JB, Adelborg K, Christensen S, Hvas AM. Dynamic hemostasis and fibrinolysis assays in intensive care COVID-19 patients and association with thrombosis and bleeding - a systematic review and a cohort study. Semin Thromb Hemost 2022;48(1):31–54 |
14 |
Schellong S, Ageno W, Casella IB, Chee KH, Schulman S, Singer DE, Desch M, Tang W, Voccia I, Zint K, Goldhaber SZ. Profile of patients with isolated distal deep vein thrombosis versus proximal deep vein thrombosis or pulmonary embolism: RE-COVERY DVT/PE study. Semin Thromb Hemost 2022;48(4):446–458 |
15 |
Leiderman K, Sindi SS, Monroe DM, Fogelson AL, Neeves KB. The art and science of building a computational model to understand hemostasis. Semin Thromb Hemost 2021;47(2):129–138 |
a 2021–2022 inclusive, as downloaded in 2022. Ranking is according to download data provided by journal publisher, and excludes most nonqualifying material (e.g., Prefaces, Errata, Letters to the Editor, Editorials, Commentaries); however, previous award-winning articles may be listed for recording purposes—these do not, however, qualify for another award.
Rank |
Publication |
|---|---|
1 |
Branstetter JW, Kiskaddon AL, King MA, Coalter C, Grubbs KM, Fly H, Male C, Brandão L, Goldenberg NA. Efficacy and safety of non-vitamin K antagonist oral anticoagulants in pediatric venous thromboembolism treatment and thromboprophylaxis: a systematic review of the literature. Semin Thromb Hemost 2021;47(6):643–653 |
2 |
Ichinose A, Osaki T, Souri M. A review of coagulation abnormalities of autoimmune acquired factor V deficiency with a focus on Japan. Semin Thromb Hemost 2022;48(2):206–218 |
3 |
Thachil J. Protamine - the journey from DNA to heparin neutralization to gene therapy. Semin Thromb Hemost 2022;48(2):240–243 |
4 |
Liesdek OCD, Urbanus RT, de Heer LM, Fischer K, Suyker WJL, Schutgens REG. Alternatives for vitamin K antagonists as thromboprophylaxis for mechanical heart valves and mechanical circulatory support devices: a systematic review. Semin Thromb Hemost 2021;47(6):724–734 |
5 |
Iba T, Levi M, Thachil J, Levy JH. Disseminated intravascular coagulation: the past, present, and future considerations. Semin Thromb Hemost 2022;48(8):978–987 |
6 |
Larsen JB, Hvas AM. Thrombin: a pivotal player in hemostasis and beyond. Semin Thromb Hemost 2021;47(7):759–774 |
7 |
Franchini M, Mannucci PM. The more recent history of hemophilia treatment. Semin Thromb Hemost 2022;48(8):904–910 |
8 |
Al-Samkari H. Systemic antiangiogenic therapies for bleeding in hereditary hemorrhagic telangiectasia: a practical, evidence-based guide for clinicians. Semin Thromb Hemost 2022;48(5):514–528 |
9 |
Ichinose A, Osaki T, Souri M, Favaloro EJ. A review of autoimmune acquired von Willebrand factor deficiency in Japan. Semin Thromb Hemost 2022;48(8):911–925 |
10 |
Carpenè G, Negrini D, Lippi G, Favaloro EJ, Montagnana M. Heparin: the journey from parenteral agent to nasal delivery. Semin Thromb Hemost 2022;48(8):949–954 |
11 |
Christiansen M, Grove EL, Hvas AM. Contemporary clinical use of aspirin: mechanisms of action, current concepts, unresolved questions, and future perspectives. Semin Thromb Hemost 2021;47(7):800–814 |
12 |
Aamodt AH, Skattør TH. Cerebral venous thrombosis. Semin Thromb Hemost 2022;48(3):309–317 |
13 |
Kjaergaard AB, Fuglsang J, Hvas AM. Anti-Xa monitoring of low-molecular-weight heparin during pregnancy: a systematic review. Semin Thromb Hemost 2021;47(7):824–842 |
14 |
Driever EG, Lisman T. Effects of inflammation on hemostasis in acutely ill patients with liver disease. Semin Thromb Hemost 2022;48(5):596–606 |
15 |
Moore GW. Testing for lupus anticoagulants. Semin Thromb Hemost 2022;48(6):643–660 |
a 2021–2022 inclusive, as downloaded in 2022. Ranking is according to download data provided by journal publisher, and excludes nonqualifying material (e.g., Prefaces, Errata, Letters to the Editor, Editorials, Commentaries, and previous award-winning articles).
Free Access Category[2] [3] [4]
Lippi G, Favaloro EJ. Cerebral venous thrombosis developing after COVID-19 vaccination: VITT, VATT, TTS, and more. Semin Thromb Hemost 2022 Feb;48(1):8–14. (Note: Authors will decline the cash prize, which publisher will assign to a third article for this category).
Engelen MM, Vandenbriele C, Balthazar T, Claeys E, Gunst J, Guler I, Jacquemin M, Janssens S, Lorent N, Liesenborghs L, Peerlinck K, Pieters G, Rex S, Sinonquel P, Van der Linden L, Van Laer C, Vos R, Wauters J, Wilmer A, Verhamme P, Vanassche T. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost 2021 Jun;47(4):362–371.
Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: a systematic review and an updated meta-analysis. Semin Thromb Hemost 2021 Jun;47(4):372–391.
Thus, the cash prize will be awarded to the authors of the second and third authorship teams of Engelen et al[3] and Parisi et al.[4] Of interest, the manuscript from Engelen et al represents the submission from a prior (2020) Young Investigator Award winner,[31] and is also an original study, thereby again validating the Young Investigator Award process as well as the journal's decision to continue to publish high-quality original studies.[32]
#
General Category[16] [17]
Branstetter J, Kiskaddon AL, King MA, Coalter C, Grubbs KM, Fly H, Male C, Brandão L, Goldenberg NA. Efficacy and safety of non-vitamin K antagonist oral anticoagulants in pediatric venous thromboembolism treatment and thromboprophylaxis: a systematic review of the literature. Semin Thromb Hemost 2021 Sep;47(6):643–653.
Ichinose A, Osaki T, Souri M. A review of coagulation abnormalities of autoimmune acquired factor V deficiency with a focus on Japan. Semin Thromb Hemost 2022 Mar;48(2):206–218.
Of further interest, there are two other previous Young Investigator Award winners listed in [Table 4]. Ellen Driever was another 2020 Young Investigator Award winner,[31] and the listed article[29] represents the submission provided as a condition of the award, so once again validating the Young Investigator Awards. Hanny Al-Samkari was also a 2020 Young Investigator Award winner,[31] and his article also represents the submission provided as a condition of the award.[23]
As always, I always get considerable satisfaction in announcing these awards. This year once again saw the topic of COVID-19 take prominence, not only worldwide but also in this journal. I predicted that COVID-19-related reviews would do well in the popular awards in an earlier (2021) editorial.[33] Thieme, the publisher of STH, was, until 2023, providing most COVID-19-related articles freely available from their Web site. To date, we have published four issues of STH related to COVID-19,[34] [35] [36] [37] and all have proven very popular with the readership. STH included a series of “editorial” commentaries early in the COVID-19 pandemic; these have also proven to be very popular with the readership, and many were listed in the top 2022 downloads list; however, these do not qualify for the Most Popular awards.
All authors of the award-winning articles were thrilled to hear that their articles had won an Eberhard F. Mammen Most Popular award, and provided their own personal responses to the news.
From Professor Giuseppe Lippi ([Fig. 2]), speaking also on my behalf, “It is a real pleasure and privilege to be granted one of the Eberhard F. Mammen Seminars in Thrombosis and Hemostasis 2023 Awards for our article entitled “Cerebral Venous Thrombosis Developing after COVID-19 Vaccination: VITT, VATT, TTS, and More.” We are pleasantly surprised to know that this article has gained interest and momentum over the past year, largely as a result of the large diffusion of COVID-19 vaccination which, as we know, is the most essential tool for managing the pandemic, but also carries some inherent risks as with the administration of any other vaccine or even common drugs (such as aspirin). This actually supports our proposal to develop a tailored (perhaps laboratory-based) model of vaccination aimed at enhancing the benefits to those who would benefit more, and minimizing the possible complications in those who could safely delay boosters. We also wish to thank the publisher for promoting the field by application of the Eberhard F. Mammen awards. We have declined the cash prize, and instead requested that the prize money funds an additional Most Popular award on this occasion, which the publisher has agreed to.”
From Matthias M. Engelen ([Fig. 3]), speaking on behalf of all authors (some of who also appear in [Fig. 3]), “We are truly honored to be granted one of two Eberhard F. Mammen awards in Seminars in Thrombosis and Haemostasis for Most Popular Article in the open access category. During the pandemic, we quickly needed answers regarding the thrombotic risk and the thromboprophylactic therapy in COVID-19 patients. We are, therefore, thrilled that our article on venous thromboembolism in patients discharged after COVID-19 hospitalization was widely read in this prestigious journal. We want to thank all collaborators for making it possible to systematically screen discharged COVID-19 patients in these challenging times. We especially thank the editor-in-chief, Emmanuel Favaloro, for reaching out to us after we presented our late-breaking data at the virtual International Society on Thrombosis and Haemostasis meeting, as indeed, it proved to be of great interest to the readers of this outstanding journal. We are very grateful to have had the opportunity to work together on publishing our findings in STH.”
From Simona Costanzo and Roberta Parisi, speaking on behalf of all authors ([Fig. 4]): “We are deeply honored to have been granted one of the “Eberhard F. Mammen Seminars in Thrombosis and Hemostasis 2023 Most Popular Article Awards” for the “Free Access Category.” We were pleasantly surprised and excited to hear that our article entitled “Different Anticoagulant Regimens, Mortality, and Bleeding in Hospitalized Patients with COVID-19: A Systematic Review and an Updated Meta-Analysis” was widely appreciated by the scientific community. The idea for our article originated following the results of the multicenter Italian CORIST study where we had observed a remarkable reduction of in-hospital COVID-19 patients' mortality associated with use of low-molecular-weight heparin [1].[38] This prompted us to define, using a large meta-analysis, the type and dosage of heparin and other anticoagulant drugs used in the management of hospitalized COVID-19 patients. Our findings, promptly published in STH, were taken into consideration by the Italian Medicines Agency (AIFA) to guide anticoagulant management of these patients [2].[39] We are glad that our article continues to capture the attention of a large proportion of the STH readership even today. We would like to thank the editors of STH for the opportunity to publish our research in this prestigious journal. This award inspires us to pursue our research to provide novel insights on the role of blood coagulation in the severity and clinical outcomes of COVID-19 patients.”
Di Castelnuovo A, Costanzo S, Antinori A, et al. Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the Multicenter Italian CORIST study. Thromb Haemost 2021;121(8):1054–1065. doi: 10.1055/a-1347-6070.
Italian Medicines Agency. Uso delle eparine nei pazienti adulti con COVID-19. Available at: https://www.aifa.gov.it/documents/20142/0/Eparine_Basso_Peso_Molecolare_13.05.2021.pdf; accessed February 11, 2023.
From Joshua W. Branstetter and Amy L. Kiskaddon ([Fig. 5]), on behalf of all authors, “We are truly privileged to receive one of the 2023 Eberhard F. Mammen Seminars in Thrombosis and Hemostasis Most Popular Article Awards. We are excited to learn that our systematic review of non-vitamin K antagonist oral anticoagulants in pediatric patients outlining both published clinical data and studies on the horizon was well received. Our manuscript outlines the emerging data regarding venous thromboembolism treatment and thromboprophylaxis with non-vitamin K antagonist oral anticoagulants in pediatric patients. The clinical use of these agents in pediatrics is rapidly increasing and we hope our manuscript will continue to serve as a succinct resource outlining this information. We would like to thank our wonderful co-authors for their contributions and input to improve the relevance of this paper. We greatly appreciate the opportunity to share this knowledge with the readership of STH, and are truly honored to have had the contribution rewarded by this honor.”
From Professor Akitada Ichinose ([Fig. 6]), speaking also on behalf of his coauthors (one of who also appears in [Fig. 6]): “We were very surprised and greatly honored to learn that our paper received one of the STH 2023 Eberhard F. Mammen Most Popular Article Awards for the ‘General Category.’ Since 2009, we have been conducting nationwide surveys on unexplained severe hemorrhagic disorders in Japan. As a result, we have established a registry of autoimmune acquired coagulation factor deficiencies due to autoantibodies against factor XIII, von Willebrand factor, factor VIII, factor V, factor X, etc. as part of the Designated Intractable Disease-288 of the Japanese Ministry of Health, Labor and Welfare and thus, we have achieved significant outcomes in providing medical and economic support to many patients. The study on autoimmune acquired factor V deficiency, which received the award on this occasion, is part of this project, and we expect that the findings reported in the manuscript will contribute to the management of more patients in the future. Finally, I would like to thank the editors of STH for giving us the opportunity to publish our work in this journal, the readers who appreciated this particular paper, and the researchers who supported our collaborative study.”
I would, as always, like to thank not only all of the authors listed in [Tables 2] to [4], but also all the other contributing authors who did not manage to make these listings, as well as all the many other guest editors of issues recently published in STH. I likewise look forward to seeing future listings—always a great pleasure and sometimes a surprise.
#
#
#
Conflict of Interest
None declared.
References
- 1 Allaoui A, Khawaja AA, Badad O. et al. Platelet function in viral immunity and SARS-CoV-2 infection. Semin Thromb Hemost 2021; 47 (04) 419-426
- 2 Lippi G, Favaloro EJ. Cerebral venous thrombosis developing after COVID-19 vaccination: VITT, VATT, TTS, and more. Semin Thromb Hemost 2022; 48 (01) 8-14
- 3 Engelen MM, Vandenbriele C, Balthazar T. et al. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost 2021; 47 (04) 362-371
- 4 Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: a systematic review and an updated meta-analysis. Semin Thromb Hemost 2021; 47 (04) 372-391
- 5 Favaloro EJ, Henry BM, Lippi G. Is lupus anticoagulant a significant feature of COVID-19? A critical appraisal of the literature. Semin Thromb Hemost 2022; 48 (01) 55-71
- 6 Abate V, Casoria A, Rendina D. et al. Spontaneous muscle hematoma in patients with COVID-19: a systematic literature review with description of an additional case series. Semin Thromb Hemost 2022; 48 (01) 100-108
- 7 Bahraini M, Dorgalaleh A. The impact of SARS-CoV-2 infection on blood coagulation and fibrinolytic pathways: a review of prothrombotic changes caused by COVID-19. Semin Thromb Hemost 2022; 48 (01) 19-30
- 8 Favaloro EJ, Henry BM, Lippi G. Increased VWF and decreased ADAMTS-13 in COVID-19: creating a milieu for (micro)thrombosis. Semin Thromb Hemost 2021; 47 (04) 400-418
- 9 Fernández-Capitán C, Barba R, Díaz-Pedroche MDC. et al. Presenting characteristics, treatment patterns, and outcomes among patients with venous thromboembolism during hospitalization for COVID-19. Semin Thromb Hemost 2021; 47 (04) 351-361
- 10 Favaloro EJ, Henry BM, Lippi G. COVID-19 and antiphospholipid antibodies: Time for a reality check?. Semin Thromb Hemost 2022; 48 (01) 72-92
- 11 Grobbelaar LM, Kruger A, Venter C. et al. Relative hypercoagulopathy of the SARS-CoV-2 beta and delta variants when compared to the less severe omicron variants is related to TEG parameters, the extent of fibrin amyloid microclots, and the severity of clinical illness. Semin Thromb Hemost 2022; 48 (07) 858-868
- 12 Onorato D, Pucci M, Carpene G, Henry BM, Sanchis-Gomar F, Lippi G. Protective effects of statins administration in European and North American patients infected with COVID-19: a meta-analysis. Semin Thromb Hemost 2021; 47 (04) 392-399
- 13 Hvas CL, Larsen JB, Adelborg K, Christensen S, Hvas AM. Dynamic hemostasis and fibrinolysis assays in intensive care COVID-19 patients and association with thrombosis and bleeding - a systematic review and a cohort study. Semin Thromb Hemost 2022; 48 (01) 31-54
- 14 Schellong S, Ageno W, Casella IB. et al. Profile of patients with isolated distal deep vein thrombosis versus proximal deep vein thrombosis or pulmonary embolism: RE-COVERY DVT/PE study. Semin Thromb Hemost 2022; 48 (04) 446-458
- 15 Leiderman K, Sindi SS, Monroe DM, Fogelson AL, Neeves KB. The art and science of building a computational model to understand hemostasis. Semin Thromb Hemost 2021; 47 (02) 129-138
- 16 Branstetter JW, Kiskaddon AL, King MA. et al. Efficacy and safety of non-vitamin K antagonist oral anticoagulants in pediatric venous thromboembolism treatment and thromboprophylaxis: a systematic review of the literature. Semin Thromb Hemost 2021; 47 (06) 643-653
- 17 Ichinose A, Osaki T, Souri M. A review of coagulation abnormalities of autoimmune acquired factor V deficiency with a focus on Japan. Semin Thromb Hemost 2022; 48 (02) 206-218
- 18 Thachil J. Protamine - the journey from DNA to heparin neutralization to gene therapy. Semin Thromb Hemost 2022; 48 (02) 240-243
- 19 Liesdek OCD, Urbanus RT, de Heer LM, Fischer K, Suyker WJL, Schutgens REG. Alternatives for vitamin K antagonists as thromboprophylaxis for mechanical heart valves and mechanical circulatory support devices: a systematic review. Semin Thromb Hemost 2021; 47 (06) 724-734
- 20 Iba T, Levi M, Thachil J, Levy JH. Disseminated intravascular coagulation: the past, present, and future considerations. Semin Thromb Hemost 2022; 48 (08) 978-987
- 21 Larsen JB, Hvas AM. Thrombin: a pivotal player in hemostasis and beyond. Semin Thromb Hemost 2021; 47 (07) 759-774
- 22 Franchini M, Mannucci PM. The more recent history of hemophilia treatment. Semin Thromb Hemost 2022; 48 (08) 904-910
- 23 Al-Samkari H. Systemic antiangiogenic therapies for bleeding in hereditary hemorrhagic telangiectasia: a practical, evidence-based guide for clinicians. Semin Thromb Hemost 2022; 48 (05) 514-528
- 24 Ichinose A, Osaki T, Souri M, Favaloro EJ. A review of autoimmune acquired von Willebrand factor deficiency in Japan. Semin Thromb Hemost 2022; 48 (08) 911-925
- 25 Carpenè G, Negrini D, Lippi G, Favaloro EJ, Montagnana M. Heparin: the journey from parenteral agent to nasal delivery. Semin Thromb Hemost 2022; 48 (08) 949-954
- 26 Christiansen M, Grove EL, Hvas AM. Contemporary clinical use of aspirin: mechanisms of action, current concepts, unresolved questions, and future perspectives. Semin Thromb Hemost 2021; 47 (07) 800-814
- 27 Aamodt AH, Skattør TH. Cerebral venous thrombosis. Semin Thromb Hemost 2022; 48 (03) 309-317
- 28 Kjaergaard AB, Fuglsang J, Hvas AM. Anti-Xa monitoring of low-molecular-weight heparin during pregnancy: a systematic review. Semin Thromb Hemost 2021; 47 (07) 824-842
- 29 Driever EG, Lisman T. Effects of inflammation on hemostasis in acutely ill patients with liver disease. Semin Thromb Hemost 2022; 48 (05) 596-606
- 30 Moore GW. Testing for lupus anticoagulants. Semin Thromb Hemost 2022; 48 (06) 643-660
- 31 Favaloro EJ. 2020 Eberhard F. Mammen Award announcements: Part II - Young Investigator Awards. Semin Thromb Hemost 2021; 47 (03) 229-237
- 32 Favaloro EJA. 2018 Update on the editorial and publication policy of Seminars in Thrombosis and Hemostasis. Semin Thromb Hemost 2018; 44 (04) 307-311
- 33 Favaloro EJ. 2022 Eberhard F. Mammen Award announcements: Part I - most popular articles. Semin Thromb Hemost 2022; 48 (05) 502-513
- 34 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19) - Part I. Semin Thromb Hemost 2020; 46 (07) 757-762
- 35 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19): Part II. Semin Thromb Hemost 2021; 47 (04) 333-337
- 36 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19) - Part III. Semin Thromb Hemost 2022; 48 (01) 3-7
- 37 Favaloro EJ, Pasalic L, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19) - Part IV. Semin Thromb Hemost 2023; 49 (01) 3-8
- 38 Di Castelnuovo A, Costanzo S, Antinori A. et al. Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the Multicenter Italian CORIST Study. Thromb Haemost 2021; 121 (08) 1054-1065
- 39 Italian Medicines Agency. Uso delle eparine nei pazienti adulti con COVID-19. Accessed February 11, 2023 at: https://www.aifa.gov.it/documents/20142/0/Eparine_Basso_Peso_Molecolare_13.05.2021.pdf
Address for correspondence
Publication History
Article published online:
20 March 2023
© 2023. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
References
- 1 Allaoui A, Khawaja AA, Badad O. et al. Platelet function in viral immunity and SARS-CoV-2 infection. Semin Thromb Hemost 2021; 47 (04) 419-426
- 2 Lippi G, Favaloro EJ. Cerebral venous thrombosis developing after COVID-19 vaccination: VITT, VATT, TTS, and more. Semin Thromb Hemost 2022; 48 (01) 8-14
- 3 Engelen MM, Vandenbriele C, Balthazar T. et al. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost 2021; 47 (04) 362-371
- 4 Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: a systematic review and an updated meta-analysis. Semin Thromb Hemost 2021; 47 (04) 372-391
- 5 Favaloro EJ, Henry BM, Lippi G. Is lupus anticoagulant a significant feature of COVID-19? A critical appraisal of the literature. Semin Thromb Hemost 2022; 48 (01) 55-71
- 6 Abate V, Casoria A, Rendina D. et al. Spontaneous muscle hematoma in patients with COVID-19: a systematic literature review with description of an additional case series. Semin Thromb Hemost 2022; 48 (01) 100-108
- 7 Bahraini M, Dorgalaleh A. The impact of SARS-CoV-2 infection on blood coagulation and fibrinolytic pathways: a review of prothrombotic changes caused by COVID-19. Semin Thromb Hemost 2022; 48 (01) 19-30
- 8 Favaloro EJ, Henry BM, Lippi G. Increased VWF and decreased ADAMTS-13 in COVID-19: creating a milieu for (micro)thrombosis. Semin Thromb Hemost 2021; 47 (04) 400-418
- 9 Fernández-Capitán C, Barba R, Díaz-Pedroche MDC. et al. Presenting characteristics, treatment patterns, and outcomes among patients with venous thromboembolism during hospitalization for COVID-19. Semin Thromb Hemost 2021; 47 (04) 351-361
- 10 Favaloro EJ, Henry BM, Lippi G. COVID-19 and antiphospholipid antibodies: Time for a reality check?. Semin Thromb Hemost 2022; 48 (01) 72-92
- 11 Grobbelaar LM, Kruger A, Venter C. et al. Relative hypercoagulopathy of the SARS-CoV-2 beta and delta variants when compared to the less severe omicron variants is related to TEG parameters, the extent of fibrin amyloid microclots, and the severity of clinical illness. Semin Thromb Hemost 2022; 48 (07) 858-868
- 12 Onorato D, Pucci M, Carpene G, Henry BM, Sanchis-Gomar F, Lippi G. Protective effects of statins administration in European and North American patients infected with COVID-19: a meta-analysis. Semin Thromb Hemost 2021; 47 (04) 392-399
- 13 Hvas CL, Larsen JB, Adelborg K, Christensen S, Hvas AM. Dynamic hemostasis and fibrinolysis assays in intensive care COVID-19 patients and association with thrombosis and bleeding - a systematic review and a cohort study. Semin Thromb Hemost 2022; 48 (01) 31-54
- 14 Schellong S, Ageno W, Casella IB. et al. Profile of patients with isolated distal deep vein thrombosis versus proximal deep vein thrombosis or pulmonary embolism: RE-COVERY DVT/PE study. Semin Thromb Hemost 2022; 48 (04) 446-458
- 15 Leiderman K, Sindi SS, Monroe DM, Fogelson AL, Neeves KB. The art and science of building a computational model to understand hemostasis. Semin Thromb Hemost 2021; 47 (02) 129-138
- 16 Branstetter JW, Kiskaddon AL, King MA. et al. Efficacy and safety of non-vitamin K antagonist oral anticoagulants in pediatric venous thromboembolism treatment and thromboprophylaxis: a systematic review of the literature. Semin Thromb Hemost 2021; 47 (06) 643-653
- 17 Ichinose A, Osaki T, Souri M. A review of coagulation abnormalities of autoimmune acquired factor V deficiency with a focus on Japan. Semin Thromb Hemost 2022; 48 (02) 206-218
- 18 Thachil J. Protamine - the journey from DNA to heparin neutralization to gene therapy. Semin Thromb Hemost 2022; 48 (02) 240-243
- 19 Liesdek OCD, Urbanus RT, de Heer LM, Fischer K, Suyker WJL, Schutgens REG. Alternatives for vitamin K antagonists as thromboprophylaxis for mechanical heart valves and mechanical circulatory support devices: a systematic review. Semin Thromb Hemost 2021; 47 (06) 724-734
- 20 Iba T, Levi M, Thachil J, Levy JH. Disseminated intravascular coagulation: the past, present, and future considerations. Semin Thromb Hemost 2022; 48 (08) 978-987
- 21 Larsen JB, Hvas AM. Thrombin: a pivotal player in hemostasis and beyond. Semin Thromb Hemost 2021; 47 (07) 759-774
- 22 Franchini M, Mannucci PM. The more recent history of hemophilia treatment. Semin Thromb Hemost 2022; 48 (08) 904-910
- 23 Al-Samkari H. Systemic antiangiogenic therapies for bleeding in hereditary hemorrhagic telangiectasia: a practical, evidence-based guide for clinicians. Semin Thromb Hemost 2022; 48 (05) 514-528
- 24 Ichinose A, Osaki T, Souri M, Favaloro EJ. A review of autoimmune acquired von Willebrand factor deficiency in Japan. Semin Thromb Hemost 2022; 48 (08) 911-925
- 25 Carpenè G, Negrini D, Lippi G, Favaloro EJ, Montagnana M. Heparin: the journey from parenteral agent to nasal delivery. Semin Thromb Hemost 2022; 48 (08) 949-954
- 26 Christiansen M, Grove EL, Hvas AM. Contemporary clinical use of aspirin: mechanisms of action, current concepts, unresolved questions, and future perspectives. Semin Thromb Hemost 2021; 47 (07) 800-814
- 27 Aamodt AH, Skattør TH. Cerebral venous thrombosis. Semin Thromb Hemost 2022; 48 (03) 309-317
- 28 Kjaergaard AB, Fuglsang J, Hvas AM. Anti-Xa monitoring of low-molecular-weight heparin during pregnancy: a systematic review. Semin Thromb Hemost 2021; 47 (07) 824-842
- 29 Driever EG, Lisman T. Effects of inflammation on hemostasis in acutely ill patients with liver disease. Semin Thromb Hemost 2022; 48 (05) 596-606
- 30 Moore GW. Testing for lupus anticoagulants. Semin Thromb Hemost 2022; 48 (06) 643-660
- 31 Favaloro EJ. 2020 Eberhard F. Mammen Award announcements: Part II - Young Investigator Awards. Semin Thromb Hemost 2021; 47 (03) 229-237
- 32 Favaloro EJA. 2018 Update on the editorial and publication policy of Seminars in Thrombosis and Hemostasis. Semin Thromb Hemost 2018; 44 (04) 307-311
- 33 Favaloro EJ. 2022 Eberhard F. Mammen Award announcements: Part I - most popular articles. Semin Thromb Hemost 2022; 48 (05) 502-513
- 34 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19) - Part I. Semin Thromb Hemost 2020; 46 (07) 757-762
- 35 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19): Part II. Semin Thromb Hemost 2021; 47 (04) 333-337
- 36 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19) - Part III. Semin Thromb Hemost 2022; 48 (01) 3-7
- 37 Favaloro EJ, Pasalic L, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19) - Part IV. Semin Thromb Hemost 2023; 49 (01) 3-8
- 38 Di Castelnuovo A, Costanzo S, Antinori A. et al. Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the Multicenter Italian CORIST Study. Thromb Haemost 2021; 121 (08) 1054-1065
- 39 Italian Medicines Agency. Uso delle eparine nei pazienti adulti con COVID-19. Accessed February 11, 2023 at: https://www.aifa.gov.it/documents/20142/0/Eparine_Basso_Peso_Molecolare_13.05.2021.pdf